Vyloy With Chemotherapy Approved for Gastric or Gastroesophageal Junction Adenocarcinoma

The FDA has approved zolbetuximab-clzb (Vyloy, Astellas Pharma), a claudin 18.2 (CLDN18.2)-directed cytolytic antibody, with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are CLDN18.2-positive, as determined by an FDA-approved test.

The FDA has also approved the VENTANA